News

Yale Cancer Center and Smilow Cancer Hospital people who have been honored

“We believe future trials will need to test whether modifying the choice of chemotherapy or adding immunotherapy could improve the chance of organ preservation,” said senior investigator Barbara A. Burtness, MD, an Anthony N. Brady professor of medicine and Chief Translational Research Officer at Yale Cancer Center, chair of the ECOG-ACRIN Head and Neck Committee, and chair of the ECOG-ACRIN Task Force on Advancement for Women.

Ania Jastreboff, MD, PhD, associate professor of medicine (endocrinology) at Yale School of Medicine, discusses the range of diseases treated by novel weight-loss drugs such as Ozempic, Mounjaro, and Wegovy.

Dr. Pamela Kunz discusses "Advances in the Care of Neuroendocrine Tumors (NETs)."

Hepatocellular carcinoma is the most common form of liver cancer in adults. Hepatitis C infection is a known cause of hepatocellular carcinoma because the virus causes chronic inflammation and scarring of the liver, known as cirrhosis. Newer anti-viral drugs offer highly effective cures for hepatitis C, leading to stabilization of hepatitis C-related liver disease and decreased rates of hepatocellular carcinoma. Although new infections can occur at any age, the “baby boomer” generation born between 1945-1965 represents the largest population affected by hepatitis C in the United States. Yale's new research looked at whether ongoing liver cancer screening for individuals who achieved hepatitis C cure improves their overall survival rates.

A new treatment for locally advanced rectal cancer (LARC) reduced the existence of tumors by twice the amount as previous approaches, eliminating the need for surgery, a new study found.

A new study led by Rachel Lampert, MD, found that patients with LQTS who receive proper risk assessment and treatment in experienced centers have low cardiac event rates whether or not they exercise vigorously. In the following Q&A, Lampert discusses the new paper, current guidelines for college athletes, and additional research necessary to guide clinicians and patients on returning to play.

On August 30 – September 2, Yale researchers will be presenting research and moderating sessions at the European Society of Cardiology’s (ESC) Congress 2024 in London. The focus of this year’s conference is personalizing cardiovascular care for patients.

On Yale Cancer Answers Dr. Tamar Taddei discusses the causes of liver disease and liver cancer and the multidisciplinary approaches to care.